ISAACS STEPHEN T 4
4 · ADURO BIOTECH, INC. · Filed Sep 6, 2018
Insider Transaction Report
Form 4
ISAACS STEPHEN T
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
[F1]2018-09-05$1.00/sh+15,585$15,585→ 221,331 total - Sale
Common Stock
[F1][F2]2018-09-05$7.90/sh−15,585$123,134→ 205,746 total - Exercise/Conversion
Common Stock
[F1]2018-09-06$1.00/sh+46,987$46,987→ 252,733 total - Sale
Common Stock
[F1][F4]2018-09-06$7.92/sh−46,987$372,024→ 205,746 total - Exercise/Conversion
Stock Option (right to buy)
[F1][F3]2018-09-05−15,585→ 810,894 totalExercise: $1.00Exp: 2024-07-30→ Common Stock (15,585 underlying) - Exercise/Conversion
Stock Option (right to buy)
[F1][F3]2018-09-06−46,987→ 763,907 totalExercise: $1.00Exp: 2024-07-30→ Common Stock (46,987 underlying)
Holdings
- 8,932(indirect: By Trust)
Common Stock
[F5]
Footnotes (5)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2017.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $7.925, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The shares subject to the Option are fully vested and exercisable.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.90 to $8.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F5]The shares owned directly by the Isaacs-MacBride Family Trust UAD 03/09/01, for which the Reporting Person is a trustee.
Signature
/s/ Blaine Templeman, Attorney-in-Fact|2018-09-06